BioSpace News Archive

Caeregen Therapeutics, a regenerative medicine therapeutics company and Wacker Biotech, a contract development and manufacturing organization, will collaborate on the development and production of CTR-107, a novel regenerative therapeutic for the treatment of retinal-related vision loss.

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors.

Pfizer Inc. and OPKO Health Inc. announced that the U.S. Food and Drug Administration has approved NGENLA, a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Synlogic, Inc. today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected “labafenogene marselecobac” for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). These data reinforce the safety and tolerability profile of FHD-286.

GeneDx today announced it will present new data on urine mitochondrial DNA testing at the 2023 United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine Symposium in Charlotte, North Carolina, June 28 - July 1, 2023.

Cognition Therapeutics, Inc. today announced topline results from its Phase 2 double-blind, single-crossover SEQUEL study (NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease.

PacBio today announced that Bioscientia is using its Revio long-read sequencing systems to expand its genomics research projects and sequence several thousand human genomes per year.

Coya Therapeutics, Inc. today announced the presentation of results from an academic clinical study in patients with Alzheimer’s Disease (AD) with subcutaneous ld IL-2 at the 2023 Alzheimer’s Association International Conference (AAIC) to be held in Amsterdam, Netherlands, from July 16-20, 2023.

Mednow Inc. (“ Mednow '' or the “ Company ”) (TSXV:MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce the Company will be hosting its quarterly conference call on Friday, June 30, 2023 at 8:30am EST.